May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system, patients with high blood pressure who did not respond to treatment with multiple ...
Hypertension
This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics and renal denervation therapy.
-
-
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had statistically significant reductions in average blood pressure over 24 hours ...
-
March 16, 2020 — The European Society of Cardiology (ESC) issued a statement March 13 recommending in novel coronavirus (COVID-19, and now clinically referred to as SARS‐CoV‐2) patients not ...
-
The U.S. Food and Drug Administration (FDA) approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other heart failure devices, such as cardiac resynchronization therapy. The FDA gave the device a Breakthrough Device designation because it treats a life-threatening disease, heart failure, and addresses an unmet medical need in patients who fail to get adequate benefits from standard treatments and have no alternative treatment options.
November 18, 2021 — Village doctors who were community health workers in rural China were trained and successfully ...
November 18, 2021
November 12, 2021 — Orchestra BioMed Inc. announced multiple presentations of long-term clinical results and ISH ...
November 12, 2021
November 9, 2021 — Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound ...
November 09, 2021
August 3, 2021 — Long-term follow-up data on hypertensive patients from the control group of the MODERATO II study who ...
August 03, 2021
Feature | Hypertension | By Dave Fornell, Editor
May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...
May 16, 2021
December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to ...
December 09, 2020
July 15, 2020 – Omron Healthcare Inc. and Mount Sinai Health System, New York City’s largest academic medical system ...
July 15, 2020
June 26, 2020 – New data from the Global SYMPLICITY Registry (GSR) showed that renal denervation (RDN) with the ...
June 26, 2020
April 30, 2020 — A large study in adolescents and children, some as young as 3 years of age, shows a link between ...
April 30, 2020
April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether ...
April 08, 2020
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...
April 01, 2020April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had ...
April 01, 2020
News | Coronavirus (COVID-19) | Dave Fornell, Editor
March 16, 2020 — The European Society of Cardiology (ESC) issued a statement March 13 recommending in novel coronavirus ...
March 16, 2020
February 27, 2020 — Aria CV Inc. completed a $31 million Series B round of financing to fund its first clinical study in ...
February 27, 2020
February 7, 2020 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Aria ...
February 07, 2020© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now